Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Quell Therapeutics scooped up $156 million in a Series B round this week. The company utilizes regulatory T cells to treat a variety of autoimmune and inflammatory diseases.
Results from its GEM-3 trial on VYJUVEK demonstrated statistical significance in its ability to promote complete wound healing within six months compared to a placebo.
In October, Vertex Pharmaceuticals announced stunning results in a type 1 diabetes patient who had been dosed with the company’s experimental therapy.
As the late-stage trials continue to progress, Talaris is rapidly ramping up its resources and investments.
The latest data from Merck and Ridgeback Biotherapeutics’ MOVe-OUT trial on the use of molnupiravir to treat COVID-19 in adults has shown a lower efficacy than previously reported.
The World Health Organization officially declared omicron – aka. B.1.1.529 – a variant of concern (VOC) on Friday.
Treatment for non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, consists mainly of lifestyle modification – specifically dieting and weight loss.
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.
The U.S. Food and Drug Administration has a very busy calendar for the end of November and beginning of December. Here’s a look.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
Bonus BioGroup’s product is back in the news again as its cell therapy promises to treat late-stage COVID-19.
Both Gilead Sciences and Merck announced they were pausing a Phase II trial of islatravir and lenacapavir in HIV.